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Abstract
Background: Recent years have seen an explosion of research pertaining to biological psychiatry, yet despite
subsequent advances in our understanding of neuroimmune communication pathways, how the brain senses and
responds to peripheral inflammation remains poorly understood. A better understanding of these pathways may be
important for generating novel therapeutics to treat many patients with chronic inflammatory diseases who also
suffer from neuropsychiatric comorbidities. Here we have systematically assessed the leukocyte infiltrate to the brain
following systemic endotoxin exposure to better understand this novel route of neuroimmune communication.
Methods: Mice were injected intraperitoneally with LPS daily for 2, 5 or 7 consecutive days. We systematically
interrogated the subsequent induction of chemokine transcription in the brain using TaqMan low-density arrays. A
combination of flow cytometry and immunohistochemistry was then used to characterise the accompanying
leukocyte infiltrate.
Results: Repeated LPS challenges resulted in prolonged activation of brain-resident microglia, coupled with an
increased local transcription of numerous chemokines. After 2 days of administering LPS, there was a marked
increase in the expression of the neutrophil chemoattractants CXCL1 and CXCL2; the monocyte chemoattractants
CCL2, CCL5, CCL7 and CCL8; and the lymphocyte chemoattractants CXCL9, CXCL10 and CXCL16. In a number of
cases, this response was sustained for several days. Chemokine induction was associated with a transient
recruitment of neutrophils and monocytes to the brain, coupled with a sustained accumulation of macrophages,
CD8+ T cells, NK cells and NKT cells. Strikingly, neutrophils, monocytes and T cells appeared to extravasate from the
vasculature and/or CSF to infiltrate the brain parenchyma.
Conclusions: Prolonged exposure to a peripheral inflammatory stimulus triggers the recruitment of myeloid cells
and lymphocytes to the brain. By altering the inflammatory or metabolic milieu of the brain, this novel method of
immune-to-brain communication may have profound implications for patients with chronic inflammatory diseases,
potentially leading to neuropsychiatric comorbidities.
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Background
Patients with chronic inflammatory diseases such as
rheumatoid arthritis, inflammatory bowel disease or
psoriasis are often further burdened with neuropsychi-
atric symptoms such as depression, anxiety and fatigue
[1–5]. These comorbidities appear to be predominantly
mediated by inflammatory cytokines, which can contrib-
ute to reduced hippocampal neurogenesis, increased ac-
tivation of the hypothalamic-pituitary-adrenal axis and
increased glial cell reactivity and neuron excitability, to-
gether with altered tryptophan metabolism [6–9]. In
keeping with this cytokine-mediated depression hypoth-
esis, treating patients with the soluble TNFα receptor
etanercept significantly ameliorated depression in pa-
tients with moderate to severe psoriasis, prior to im-
provements to disease severity [3]. Moreover, treating
patients with type I IFNs can result in depression as a
major side effect [10]; one which can even recur long
after treatment stops [11]. Cytokine-mediated behav-
ioural changes have also been reported in animal
models. For example, injecting mice with lipopolysac-
charide (LPS) induces a host of sickness and depression-
like behaviours [6, 12], mostly attributed to the central
induction of inflammatory cytokines such as IL-1β,
TNFα and type I IFNs [6, 13]. However, despite an
abundance of causal links between inflammatory cyto-
kines and neuropsychiatric symptoms, we have much to
learn about how the brain senses and responds to per-
ipheral immune challenges.
Neuroimmune communication is multifactorial and
has been reviewed extensively elsewhere [14]. In addition
to inflammation-mediated stimulation of neuronal cir-
cuits in the periphery, and humoral routes of communi-
cation whereby inflammatory cytokines can stimulate
the blood-brain barrier (BBB), perivascular macrophages
or microglia within circumventricular organs, recent
publications suggest that leukocytes can be recruited to
the brain even in the absence of overt inflammation in
the central nervous system (CNS) itself [15–17]. Pre-
sumably driven by chemokines, this phenomenon could
serve as an additional and mostly overlooked route in
which a systemic immune response could influence
brain function.
We have previously shown that continuous LPS expos-
ure in the periphery resulted in a dampening of inflam-
matory gene expression by peripheral blood leukocytes,
consistent with endotoxin tolerance, but sustained ex-
pression of Il1b, Tnfa and Cxcl10 in the brain [13].
Using a similar model, He et al. demonstrated the induc-
tion of several chemokine transcripts in the brain 12 h
after a systemic LPS injection [17]. Crucially, after three
daily LPS injections, the authors observed an accumula-
tion of NK cells and neutrophils in the brain [17]. How-
ever, it has yet to be established whether these cells
cross the BBB or blood-CSF barrier to enter the brain
parenchyma, or LPS merely results in enhanced
leukocyte marginalisation to the vasculature as has been
reported previously following a single systemic LPS in-
jection [18, 19]. It is also not clear what other leukocyte
populations may also be recruited. Here we have built
on these findings. Using unbiased approaches, we have
systematically characterised chemokine induction and
leukocyte recruitment in the brain over the course of
7 days following daily LPS injections. We show that con-
tinuous systemic LPS exposure induces the expression of
multiple chemokines in the brain and drives the recruit-
ment of various populations of myeloid cells and lym-
phocytes to the brain parenchyma, even after the
peripheral inflammatory response to LPS has subsided.
By altering the central inflammatory milieu, this influx
of leukocytes may have the potential to drastically im-
pact brain homeostasis resulting in altered mood and
behaviour.
Materials and methods
Mice
Wild-type C57Bl/6 mice were purchased from Harlan
Laboratories (Indianapolis, IN) and maintained in stand-
ard caging under specific pathogen-free conditions in
the Central Research Facility, University of Glasgow. Fol-
lowing at least 1 week of acclimatisation, mice were
injected intraperitoneally (i.p.) with 50 μg LPS derived
from Escherichia coli serotype 055:B5 (Sigma Aldrich,
MO, USA), or an equivalent volume of PBS, daily for up
to 7 days. Mice were euthanised by CO2 exposure and
perfused for 5 min with 20ml PBS before tissue harvest.
All experiments were performed on 8-week-old male
mice under the auspices of UK Home Office licences.
Preparation of single-cell suspensions
Single-cell suspensions were generated from the brain
tissue by enzymatic digestion and the removal of myelin
as described previously [15]. Briefly, the brains were ex-
cised from perfused mice, finely minced using a surgical
blade and digested in HBSS containing 6 μg/ml Liberase
TM, 5 U/ml DNase I and 25mM HEPES (all from Sigma
Aldrich, St Louis, MO) for 45 min at 37 °C. Digests were
then passed through a 70-μm cell strainer and washed
twice in FACS buffer (PBS containing 2mM EDTA
(Sigma Aldrich, St Louis, MO) and 10% foetal calf serum
(FCS - Thermo Fisher Scientific, Waltham, MA)). Mye-
lin was removed from the samples using myelin removal
beads (Miltenyi, Cologne, Germany) in accordance with
the manufacturer’s instructions.
To generate single-cell suspensions of peripheral blood
leukocytes (PBL), the whole blood was collected from
the ascending aorta, centrifuged at 400 g for 5 min and
re-suspended in Red Blood Cell Lysis Buffer (Miltenyi,
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Cologne, Germany). After 10 min, cells were washed in
FACS buffer and resuspended either in FACS buffer, for
downstream flow cytometric analyses, or RLT buffer
(Qiagen, Hilden, Germany) for subsequent RNA extrac-
tion and transcriptional analyses.
Flow cytometry
Aliquots of up to 3 × 106 cells were blocked using an
anti-CD16/CD32 blocking antibody (BioLegend, San
Diego, CA) and labelled with fluorescently conjugated
antibodies in the dark as described previously (Thomson
et al. 2018). The following antibodies were purchased
from BioLegend: CD4-AF488 (GK1.5), CD8α-PE/Cy7
(53-6.7), CD11b-PE (M1/70), CD44-BV421 (IM7),
CD45-BV510 (30-F11), CD45-PE/Cy7 (30-F11), CD62L-
PE (MEL-14), CD64-APC (X54-5/7.1), F4/80-FITC
(BM8), Ly6G-AF700 (1A8), MHCII-BV510 (M5/
114.15.2), NK1.1-BV605 (PK136) and TCRβ-PerCP/
Cy5.5 (H57-597). The following were purchased from
eBioscience (San Diego, CA): CD11b-AF700 (M1/70)
and Ly6C-eFluor 450 (HK1.4). Dead cells were excluded
from analysis using Fixable Viability Dye eFluor 780
(eBioscience, San Diego, CA). Cells were analysed using
an LSRII (BD Biosciences, San Jose, CA). Data were ana-
lysed using FlowJo v10 (Tree Star, Ashland, OR).
ELISA
The concentrations of IL-1β, TNFα and IL-6 present in
blood plasma were established using DuoSet ELISA Kits
(R&D Systems, Minneapolis, MN) in accordance with
manufacturer’s guidelines.
RNA extraction and cDNA synthesis from the brain and
PBL
The brains were cut in two, the meninges removed, and
the right hemisphere was snap-frozen in liquid nitrogen
and stored at − 80 °C until required. Under RNase-free
conditions, half-brains were homogenised in 2 ml TRIzol
Reagent (Thermo Fisher Scientific, Waltham, MA) using
the TissueLyser LT (Qiagen, Hilden, Germany) and 5
mm Stainless Steel Beads (Qiagen, Hilden, Germany).
RNA was then extracted from the homogenised tissue
using the TRIzol Plus RNA Purification Kit (Thermo
Fisher Scientific, Waltham, MA) in accordance with
manufacturer’s instructions. Genomic DNA was elimi-
nated from the columns using RNase-Free DNase kits
(Qiagen, Hilden, Germany). PBL were isolated from the
whole blood, as described above, and lysed in RLT buf-
fer. Under RNase-free conditions, RNA was extracted
using RNeasy Micro Kits (Qiagen, Hilden, Germany).
RNA from the brain and PBL was reverse transcribed to
cDNA either with the Quantitect Reverse Transcription
Kit (Qiagen, Hilden, Germany) using random primers
for downstream QPCR analyses or with the high-
capacity RNA-to-cDNA kit (Thermo Fisher Scientific,
Waltham, MA) for TaqMan low-density arrays.
TaqMan low-density arrays
Chemokine transcription was assessed using custom-
made TaqMan low-density array (TLDA) microfluidic
cards (Applied Biosystems, Foster City, CA) as described
previously [20]. Briefly, 100 μl of reaction mix, contain-
ing a 1:1 mixture of cDNA (from ~ 1 μg total RNA) in
RNase-free water and 2x TaqMan Universal PCR Master
Mix (Thermo Fisher Scientific, Waltham, MA), was
loaded onto cards containing the primers and probesets
for 32 genes. Cards were centrifuged to distribute the re-
action mixture throughout the fluidic system and run on
a Prism 7900HT Fast Real-Time PCR System (Thermo
Fisher Scientific, Waltham, MA). Data were analysed
using SDS2.2 software and RQ Manager. Relative gene
expression was first normalised to the expression of
housekeeping gene Tbp, which encodes TATA-binding
protein, and then normalised to that of a calibrator se-
lected arbitrarily from the vehicle control group. Fold
change of gene expression in LPS-challenged mice com-
pared to vehicle controls was calculated using the ΔΔCT
method.
Quantitative real-time polymerase chain reactions
QPCR were performed in triplicate using 2x PerfeCTa
SYBR Green Fast Mix (Quanta Biosystems, Gaithers-
burg, MD) as described previously [21], with reactions
containing cDNA template and a 500-μM mix of for-
ward and reverse primers. Primer sequences were de-
signed using Primer3 Input Software (version 0.4.0) and
manufactured by IDT technologies. Primer sequences
are as follows: Ccl3: 5′-CAGCCAGGTGTCATTTTC
CT-3′ and 5′-CAGGCATTCAGTTCCAGGTC-3′; Ccl5:
5′-CTACTGCTTTGCCTACCTCT-3′ and 5′-ACACAC
TTGGCGGTTCCTT-3′; Cxcl1: 5′-GCTTGCCTTG
ACCCTGAA-3′ and 5′-TGTCTTCTTTCTCCGTTA
CTTGG-3′; Cxcl2: 5′-AAGTTTGCCTTGACCCTGAA-
3′ and 5′-TCTCTTTGGTTCTTCCGTTG-3′; Ccr1: 5′-
GCCCTCATTTCCCCTTCAA-3′ and 5′-CGGCTT
TGACCTTCTTCTCA-3′; Ccr3: 5′-GATTGCCTAC
ACCCACTGCT-3′ and 5′-CGGAACCTCTCACC
AACAA-3′; Ccr5: 5′-TTTGTCCTGCCTTCAGACC-3′
and 5′-TTGGTGCTCTTTCCTCATCTC-3′; Cxcr2: 5′-
TGTCTGCTCCCTTCCATCTT-3′ and 5′-CCATTT
CCTCTCCTCCACCT-3′; Cxcr3: 5′-AGTGCTTGTC
CTCCTTGTAGTTG-3′ and 5′-GGTGTTGTCCTTGT
TGCTGA-3′ and Tbp: 5′-TGCTGTTGGTGATTGTTG
GT-3′ and 5′-AACTGGCTTGTGTGGGAAAG-3′.
QPCR reactions were run for 40 cycles on a Prism
7900HT Fast Real-Time PCR system (Thermo Fisher
Scientific, Waltham, MA). Gene expression data were
first normalised to the expression of Tbp. Fold change
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values were calculated by comparing the normalised
gene expression values of each sample to the mean ex-
pression level of the control group using the ΔΔCT
method [21].
Immunohistochemistry
The brains extracted from LPS-treated and naïve control
mice were formalin-fixed and embedded in paraffin. The
brains were sliced using a precision adult brain slicer
matrix to allow for the consistent histological analysis of
coronal brain sections from specific regions of the brain
(frontal lobe, parietal-temporal lobes and cerebellum)
that were highly comparable between samples. Immuno-
histochemistry was performed on brain tissue sections
by the Veterinary Diagnostic Service Facility at the Uni-
versity of Glasgow. Slides were stained with antibodies
specific to CD3ε (SP7) (Vector Laboratories, Burlingame,
CA), S100A9/calprotectin (MAC387) and myeloperoxi-
dase (GA511) (Dako, Jena, Germany). For leukocyte
quantification, immunoreactive cells were counted blind
from three coronal sections per mouse, scanned at ×40
magnification. Cells were considered to be associated
with the blood vessels or meninges if they appeared
within < 1 mm of either structure.
Statistical analysis
Data were analysed using Prism 6 software (GraphPad,
San Diego, CA). Statistical tests used are included in the
figure legends.
Results
Daily intraperitoneal injections of LPS dampen the
peripheral inflammatory milieu
Using a previously published model of chronic LPS ex-
posure [13], mice were injected intraperitoneally (i.p.)
with 50 μg LPS every 24 h for up to 7 days (Supplemen-
tary Figure 1A-B). This triggered a significant drop in
body weight and a substantial and sustained increase in
the proportions of neutrophils and monocytes present in
the circulation that persisted throughout the time period
(Supplementary Figure 1B-D). Six hours following a sin-
gle LPS injection, both IL-1β and IL-6 were significantly
elevated in the circulation (Supplementary Figure 1E),
but no TNFα was detected at this time point, consistent
with previous reports [13, 22]. At later time points, nei-
ther IL-1β nor TNFα could be detected in the circula-
tion following recurrent injections of LPS, despite the
continued presence of increased numbers of monocytes
and neutrophils that can produce these cytokines in re-
sponse to LPS [23]. Although the level of IL-6 remained
significantly elevated in the circulation of LPS challenged
mice on day 2, this returned to baseline at later times
(Supplementary Figure 1E). These data are in keeping
with previous reports that recurrent systemic LPS
challenges result in a dampening of the peripheral in-
flammatory milieu [13, 24].
Daily LPS challenge triggers a sustained induction of
inflammatory chemokines in the brain
Flow cytometric analysis showed that microglia in the
brains of LPS-challenged mice acquired a reactive
phenotype [25], as indicated by increased expression of
CD45, F4/80 and CD64 (Fig. 1a–c). Despite the lack of
circulating IL-1β, TNFα and IL-6 at days 5 and 7, micro-
glia remained activated throughout the model. This was
associated with elevated expression of genes encoding a
number of chemokines in the brain, as indicated by
TLDA assays and validation of the most highly
expressed transcripts using QPCR (Fig. 2a, b, Supple-
mentary Figure 2A). On day 2, Ccl2, Ccl5, Ccl7, Ccl8
and Ccl11 were significantly upregulated in the brains of
LPS-challenged mice compared with brains from PBS
injected control mice, as were Cxcl1, Cxcl2, Cxcl3, Cxcl5,
Cxcl9, Cxcl10 and Cxcl16 (Fig. 2a, b, Supplementary
Figure 2A). By day 5, most chemokine transcripts began
returning to baseline levels, but Ccl8, Ccl11 and Cxcl16.
Ccl11 and Cxcl16 remained increased until the end of
the experiment on day 7. Interestingly, QPCR analysis
showed that the induction of Ccl3, Ccl5, Cxcl1 and
Cxcl2 expression in the brain was not mirrored by simi-
lar changes in peripheral blood leukocytes (PBL) (Sup-
plementary Figure 2A), as has been previously described
for Cxcl10, suggesting that chemokine transcription may
be regulated independently in the brain.
We next assessed the expression in the brain of genes
encoding the CCR1, CCR3, CCR5, CXCR2 and CXCR3
receptors that account for much of the binding of the
chemokine ligands we found to be upregulated after LPS
injection. On day 2, transcript levels of Ccr1, Cxcr2 and
Cxcr3 were significantly elevated in brain tissue by ~ 6.7-
fold, ~ 46.6-fold and ~ 1.8-fold, respectively (Supplemen-
tary Figure 2B). By day 5, transcript levels of Ccr1 and
Cxcr2 had begun to return to baseline, whereas Cxcr3
transcript levels remained elevated after 7 days of daily
LPS exposure. No significant increase in Ccr3 or Ccr5
mRNA was observed at any of the time points analysed,
although there was a trend towards an upregulation of
both chemokine receptors at days 5 and 7. Multiple LPS
injections had no significant impact on the transcript
levels of either Cxcr2 or Cxcr3 in PBL at any time and
although Ccr1 and Ccr5 mRNA levels were significantly
elevated in PBL at day 2, these had returned to baseline
by day 5 (Supplementary Figure 2B). Therefore, chemo-
kine receptor transcripts were either independently reg-
ulated in the brain or were differentially represented
following the local recruitment of chemokine-receptor
bearing leukocytes to the brain.
Thomson et al. Journal of Neuroinflammation           (2020) 17:94 Page 4 of 15
Repeated systemic LPS challenges trigger a robust
recruitment of leukocytes to the brain
To test whether the brain-specific increase in Ccr1,
Cxcr2 and/or Cxcr3 transcripts was a downstream effect
of leukocyte recruitment to the brain, we used flow cy-
tometry to look for infiltrating leukocytes and identified
as CD45hi to distinguish them from brain-resident
CD45int microglia (Fig. 1c; Supplementary Figure 3).
After 2 days of administering LPS, there was a highly sig-
nificant increase in both the proportion of CD45hi cells
(7.2-fold) and CD45 transcript levels (3.7-fold) in the
brain compared with PBS-treated controls (Supplemen-
tary Figure 3B-D). The proportion of CD45hi cells
remained increased on days 5 and 7 (3.9-fold and 2.7-
Fig. 1 Daily systemic LPS challenges increased microglial reactivity. Mice were injected daily with LPS or vehicle (PBS) i.p. for 2, 5 or 7 days and
sacrificed 24 h following the final injection. a Flow cytometry gating strategy and representative flow cytometry plots showing CD45int microglia
in the brain of vehicle (left panels) or LPS (right panels) injected mice. b Representative histograms and c quantification of the mean fluorescence
intensity (MFI) of CD45, F4/80 and CD64 expression by CD45int microglia in the brains of mice injected with LPS for 2, 5 or 7 consecutive days,
compared with mice injected with vehicle. A control sample from the vehicle-injected day 2 group was used for comparison in b. Data show
means ± 1SD. Significance was calculated using two-way ANOVA: *p≤ 0.05, ***p≤ 0.001, ****p≤ 0.0001; n = 3 (vehicle), n = 5 (LPS). Data are
representative of two independent experiments
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fold, respectively), although these later changes did not
attain statistical significance. Due to variations in the
cellularity of single-cell suspensions of the brain follow-
ing myelin removal, we were unable to accurately calcu-
late absolute numbers.
CXCL1 and CXCL2 are known neutrophil chemoat-
tractants, and the substantial upregulation of their tran-
scription in the brain (~ 41.2-fold and ~ 114.6-fold
respectively) was associated with a marked increase in
CD11b+Ly6CintLy6Ghi neutrophils in the brain at day 2
(Supplementary Figure 4A, Fig. 3a). This coincided with
the peak of disease as assessed by weight loss and gen-
eral appearance (Supplementary Figure 1B). These
neutrophils were phenotypically distinct from those in
the bloodstream of vehicle-injected control mice, ex-
pressing higher levels of F4/80 and lower levels of Ly6G
on days 2 and 5 (Fig. 3b). Consistent with the upregu-
lated levels of mRNA for the monocyte-attracting che-
mokines CCL2, CCL5, CCL7, CCL8 and CXCL3, there
were also increases in the proportions of CD11b+Ly6-
ChiF4/80+ monocytes and MHCII+ and MHCII−
CD11b+Ly6C− F4/80+ macrophages in the brain of LPS-
injected mice at this time point (Supplementary Figure
4A, Fig. 3c). Although the numbers of monocytes and
MHCII+ macrophages returned to baseline by day 5, the
numbers of CD45hiMHCII− macrophages remained
Fig. 2 Chemokine transcription was induced in the brain in response to systemic LPS challenges. Relative expression of a genes encoding CC
chemokines and b genes encoding CXC and CX3C chemokines in the brains of mice challenged daily with LPS for 2, 5 and 7 days compared
with vehicle-injected controls. Gene expression analysis was performed using TaqMan low-density arrays and normalised to Tbp. Fold change was
calculated by comparing normalised expression of each gene to that of a calibrator from the vehicle-injected control group using the ΔΔCT
method. Data show means ± 1SEM. Significance was calculated using two-way ANOVA: *p ≤ 0.05, **p≤ 0.01, ***p≤ 0.001; n = 5 per group
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significantly higher throughout the brain at all times
after LPS injections (Fig. 3c).
The brain-specific upregulation of Ccl3, Ccl5, Cxcl9
and Cxcl10, together with increased levels of Ccr1 and
Cxcr3 mRNA, prompted us to examine whether lympho-
cytes were also recruited to the brain in response to
LPS. Indeed, there were significant increases in CD8+ T
cells, NK cells and NKT cells in the brains of LPS-
Fig. 3 Myeloid cells and lymphocytes were recruited to the brain following peripheral LPS exposure. Recruitment of CD45hi leukocytes to the
brain after daily injections of LPS or vehicle for 2, 5 and 7 days as assessed by flow cytometry. a Percentage of CD11b+Ly6G+Ly6Cint neutrophils as
a proportion of all single, live, CD45+ cells in the brain. b Mean fluorescence intensity of F4/80 and Ly6G expression by neutrophils in the brains
of LPS-challenged mice compared with neutrophils in the blood of vehicle and LPS-injected mice. c Percentage of CD11b+Ly6G−Ly6C+
monocytes, CD11b+F4/80+Ly6C− macrophages and d CD4+ T cells, CD8+ T cells, NK1.1+TCRβ− NK cells and NK1.1+TCRβ+ NKT cells as a proportion
of all single, live, CD45+ cells in the brain. For gating strategy, see Supplementary Figure 4. Data show means ± 1SD. Significance was calculated
using two-way ANOVA: *p≤ 0.05, **p≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; n = 3 (vehicle), n = 5 (LPS). Data are representative of two
independent experiments
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challenged mice throughout the experiment, although
the numbers of CD4+ cells did not change (Supplemen-
tary Figure 4B, Fig. 3d). T cells in the brain were almost
exclusively effector memory cells, due to their high ex-
pression of CD44 and absence of CD62L expression
(Supplementary Figure 4B). Thus, the enhanced early
transcription of chemoattractants in the brain induced
by LPS was accompanied by transient recruitment of
myeloid cells to the brain, together with more sustained
accumulation of lymphocytes.
Recruited leukocytes infiltrate the brain parenchyma
Previous studies have shown an increase in the rolling
and tethering of neutrophils to the luminal surface of
the BBB following acute systemic exposure to LPS [18,
19]. To establish whether the increase in leukocyte pop-
ulations in the brain we found after more chronic expos-
ure to LPS also reflected enhanced marginalisation to
the vasculature, we stained tissue sections with anti-
bodies specific for the inflammatory myeloid cell
markers calprotectin (CALP) (Fig. 4a) and myeloperoxi-
dase (MPO) (Fig. 4b). Although both of these markers
can be expressed by neutrophils, monocytes and macro-
phages under different circumstances [26, 27], CALP-
expressing cells were mononuclear and resembled either
monocytes (adhered to the vasculature or ventricular
space) or macrophages (in parenchyma) (Fig. 4a),
whereas MPO expression in the brain was restricted to
polymorphonuclear cells (Fig. 4b). Not only could these
putative neutrophils and monocytes/macrophages be
found in close proximity to the vasculature, but they
were also detectable in the meninges and the ventricles
and frequently appeared to be located within the paren-
chyma itself (Fig. 4a, b, and d). Consistent with the flow
cytometry data, MPO+ polymorphonuclear cells were
only found in the brain after 2 days of injecting LPS
(Fig. 4b, d). In contrast, CALP expressing mononuclear
cells were undetectable at day 2, but could occasionally
be found in the meninges and in close proximity to the
blood vessels on day 5. They could also be found in loca-
tions consistent with parenchyma on day 7 (Fig. 4b and
data not shown).
Consistent with the flow cytometry data, CD3+ T lym-
phocytes were present throughout the brain at all times
after injection of LPS, whereas they were rarely found in
the control brains (Fig. 4c, d and data not shown). Al-
though the location of T cells was consistent with the
brain parenchyma, they could also be found in the men-
inges and associated with the blood vessels (Fig. 4c, d).
Collectively, these data confirm that prolonged exposure
to LPS in the periphery results in accumulation of mye-
loid and lymphoid cells in the meninges and in close
proximity to the brain vasculature. Leukocytes could also
be found frequently in locations consistent with infiltra-
tion of the brain parenchyma itself.
Discussion
Here we have demonstrated that repeated intraperito-
neal LPS challenges trigger a strong transcriptional up-
regulation of neutrophil chemoattractants CXCL1,
CXCL2 and CXCL5 in the brain, along with enhanced
expression of various chemokines involved in attracting
monocytes (e.g. CCL2, CCL3, CCL5, CCL7, CCL8,
CXCL3), T cells (e.g. CCL5, CXCL9, CXCL10) and NK
cells (e.g. CXCL9, CXCL10, CXCL16). This was coupled
with a transient influx of neutrophils and monocytes, and
a more sustained presence of macrophages, CD8 T cells,
NK cells and NK T cells in the brain throughout the
model (Fig. 5). The temporal pattern of leukocyte recruit-
ment mimics a classic anti-bacterial or anti-viral response,
with innate cells being the first responders, triggering en-
hanced lymphocyte-mediated immune surveillance.
By demonstrating that long-term peripheral LPS ad-
ministration induces the robust and sustained transcrip-
tional upregulation of a wide range of chemokines in the
brain, this study extends our previous findings that in-
flammatory cytokines and interferon-stimulated genes
are upregulated specifically in the brain in the same
model [13]. It also builds on findings by He et al. show-
ing the induction of an almost identical panel of chemo-
kine transcripts 12 h following a single peripheral LPS
injection [17]. Furthermore, others using less compre-
hensive approaches have reported elevated levels of
CCL2, CCL3 and CCL5 in the brain but not the serum
following multiple LPS challenges within a 24-h period
[28]. In keeping with peripheral LPS tolerance having
developed in our protocol, the pattern of response we
found here in the brain was distinct from that of periph-
eral blood leukocytes, both in terms of magnitude and
duration; crucially it was also associated with an accu-
mulation of myeloid cells and lymphocytes in the brain.
While the leukocytes appeared to be situated throughout
the parenchyma, they could also be detected in the men-
inges, the ventricles and near to the vasculature. Add-
itional imaging techniques will be required to determine
whether these cells are located within the blood vessels
themselves or are simply in close proximity to the vascu-
lature. Another limitation of this study is the unbiased
approach taken, using the whole brain RNA to compare
chemokine transcription in the brains of vehicle- and
LPS-challenged mice. While we are able to clarify that
chemokines are induced in the brain, at least at a tran-
scriptional level, further work using immunostaining
and/or fluorescent in situ hybridisation would be re-
quired to establish the anatomical location and cellular
sources of these chemokines and to confirm that our
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Fig. 4 (See legend on next page.)
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transcriptional data reflects the inflammatory protein
milieu in the brain.
The route and mechanisms by which leukocytes enter
the brain parenchyma in the response to a peripheral in-
flammatory stimulus remain unclear. Several groups
have shown that chemokine induction in the brain can
induce leukocyte infiltration, both under neuroinflam-
matory and neurodegenerative disorders [29–31], in re-
sponse to peripheral inflammation [15–17] and during
CNS viral infection [20, 32, 33]. Chemokines are known
to trigger integrin-mediated binding of immune cells to
vascular surfaces [34, 35], playing a key role in the traf-
ficking of immune cells between meningeal blood
vessels, the meninges and CSF [36], and extravasation
across the BBB [37]. As such, it seems likely that the
production of chemokines in the brain allows leukocyte
populations to migrate across the blood vessels and
enter the CSF and/or brain parenchyma. This would be
consistent with our findings that neutrophils, monocytes
and T cells could all be detected in the meninges follow-
ing repeated administration of LPS. We also observed
neutrophils and T cells in close proximity to blood ves-
sels and ventricles. However, more often they appeared
to be distributed throughout the parenchyma and not
closely associated with the vasculature. Leukocyte re-
cruitment to the brain is possibly aided by impaired
(See figure on previous page.)
Fig. 4 Leukocytes were recruited to the vasculature, meninges and brain parenchyma. Leukocyte distribution throughout the brain following
daily injections of LPS for 2, 5 or 7 days. a Representative images showing CALP+ cells in the meninges at day 5, and amongst the cortex,
ventricular space (V) and surrounding parenchyma at day 7. No CALP+ cells could be seen in untreated control mice (day 0). SA, sub-arachnoid
space; CA3, hippocampal region; DG, dentate gyrus. b MPO+ cells in the blood vessels (BV), the meninges and the parenchyma at day 5
compared to control mice (day 0). c CD3+ cells in BV, meninges, lateral ventricle (LV) and surrounding cerebral cortex at day 5 compared to
control mice (day 0). CA1, hippocampal region. d Quantification of MPO+ polymorphonuclear cells (left) and CD3+ T cells in meninges,
parenchyma, blood vessels and whole brain. Data are presented as number of cells per coronal section +/− SEM. Three coronal sections from
equivalent brain regions were analysed per sample. Significance was calculated using two-way ANOVA: **p≤ 0.01, ***p ≤ 0.001 compared to
control (day 0). n = 3/group
Fig. 5 The response of the brain to acute and prolonged endotoxin exposure. (1) A single systemic challenge with LPS activates peripheral innate
immune cells such as monocytes (Mo) and neutrophils (PMN) via TLR4. This triggers the release of inflammatory cytokines into the circulation,
activating the cerebral endothelium and perivascular macrophages (PVM) in the circumventricular organs, which then relay inflammatory signals
to the brain. Following 2 consecutive challenges, inflammatory cytokine and chemokine transcripts are upregulated in the brain. This leads to a
leaky blood-brain barrier and a transient recruitment of neutrophils and monocytes to the vasculature and brain parenchyma. (2) After repeated
systemic exposure to LPS, endotoxin tolerance means there is little response in the peripheral immune system, but this does not appear to occur
in the brain itself [13], where there continues to be increased transcription of inflammatory cytokines and chemokines. This leads to persistent
infiltration by macrophages (MØ), T cells, NK cells and NK T cells. By amplifying local inflammatory responses, this sustained recruitment of
peripheral leukocytes to the brain will potentiate LPS-mediated behavioural changes
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vascular integrity, as has been described following a sin-
gle dose of LPS [17, 38]. While we cannot rule out the
possibility that local proliferation of brain-resident mac-
rophages and patrolling memory T cells could contrib-
ute to the phenotypes described here, the healthy brain
is devoid of neutrophils. Thus, the substantial increases
in neutrophil numbers we observe in the brain are al-
most certainly recruited from the periphery.
The brain-specific chemokine induction triggered by
repeated administration of LPS was paralleled by an in-
crease in mRNA encoding CCR1 (binds CCL3, 5, 7, 14,
15, 16 and CCL23), CXCR2 (binds CXCL1-5, 7 and 8)
and CXCR3 (binds CXCL9-11). There was also a trend
towards an upregulation of both CCR3 (binds CCL5, 7,
11, 13 and 26) and CCR5 (binds CCL3, 4, 5 and 8)
mRNA in the brain at days 5 and 7. Although some of
these receptors can be expressed by neurons and glial
cells [39, 40], we believe the increases in chemokine re-
ceptor transcripts we observed are due to the increased
numbers of leukocytes expressing these receptors in the
brain, as these two processes showed similar patterns.
For example, Cxcr2 and Ccr1, expressed mainly by neu-
trophils and monocytes respectively, were elevated at
day 2 of the LPS model, at the same time as neutrophil
and monocyte numbers were increased in the brain. In
addition, Cxcr3, expressed by T cells and NK cells was
elevated throughout the model, reflecting a steady influx
of T cells and NK cells at all time points. However, we
cannot rule out the possibility that systemic LPS chal-
lenges also result in the regulation of chemokine recep-
tor transcripts by brain-resident neurons and glial cells.
Together, these findings clearly demonstrate that leuko-
cytes accumulate within the brain in response to sys-
temic LPS exposure, both in the region of the blood-
brain barrier level and possibly in the parenchyma itself,
and that this may be mediated by inflammatory chemo-
kine production.
NK cells have been shown to produce neutrophil-
recruiting chemokines after being cocultured with
microglia [17]; thus, it is possible that an early recruit-
ment of NK cells is responsible for the subsequent accu-
mulation of neutrophils in this model. In fact, the
authors demonstrated that the recruitment of NK cells
to the brain following daily peripheral LPS injections
preceded that of neutrophils by a matter of hours and
that depleting NK cells prevented neutrophil and mono-
cyte accumulation in the brain [17]. Here we have ex-
tended these findings, particularly by looking at the
kinetics of these responses over a longer time. We have
characterised the transcriptional chemokine response in
the brain in unprecedented detail over this time frame
and have used a combination of flow cytometric analyses
and immunohistochemistry to assess the entire
leukocyte infiltrate. Not only do we demonstrate that
neutrophil and monocyte accumulation is transient, but
also we show the recruitment of additional leukocyte
populations, including macrophages, CD8+ T cells and
NK cells, and crucially, our data appear to show the
presence of leukocyte populations within the brain par-
enchyma. The extent of leukocyte distribution through-
out the brain is a novel and surprising finding,
particularly as others have only noted the presence of
leukocytes within the cerebral vasculature [18, 19, 41].
The exact location of the infiltrating cells will require
further studies using 3-dimensional imaging techniques.
Leukocyte recruitment to the brain after repeated per-
ipheral administration of a TLR ligand may seem coun-
terintuitive, particularly when this protocol leads to
tolerance in the periphery. However, this process may be
one way in which the brain prepares to protect itself
against potential invasion by an organism present else-
where in the body. Nevertheless, cells such as neutro-
phils and Ly6Chi monocytes are also highly associated
with causing bystander tissue damage, making this seem
a risky reaction in such a fragile tissue [42–44]. One
possible explanation could be that some of these re-
cruited cells represent the heterogeneous population col-
lectively termed myeloid suppressor cells (MDSC),
which show similarities to both neutrophils and mono-
cytes and which can have anti-inflammatory properties,
including suppression of T cell functions [45]. This is
supported by the cell surface phenotype of the neutro-
phils we found in the brain, which had a more immature
phenotype than steady-state blood neutrophils, a pheno-
type associated with MDSC [46]. Another possibility is
that recently recruited Ly6Chi monocytes differentiate
into tissue-resident macrophages, including microglia,
during the resolution of inflammation, again offering the
potential for tissue protection and/or repair [47]. This
has been described in Alzheimer’s disease, during which
recruited monocytes differentiate into microglial-like
cells and aid in the clearance of amyloid plaques [48].
Thus, the recruitment of immature monocytes and neu-
trophils to the brain of LPS treated mice may actually
reflect an attempt to protect the brain from tissue dam-
age during the systemic inflammatory response. Para-
doxically, at least some of the infiltrating mononuclear
cells expressed the inflammatory marker calprotectin.
Although monocyte and macrophage recruitment to the
brain was greatest at days 2 and 5 of the LPS model, cal-
protectin reactivity could not be detected in the brain
until day 7. Transcriptional profiling data shows that
while calprotectin is expressed by bone-marrow mono-
cytes, it is not expressed by circulating blood monocytes
(Immunological Genome Project [49]), suggesting that it
may be induced on monocytes and macrophages after
they have been exposed to the environmental milieu of
certain tissues, in this case, the brain. This is supported
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by the fact that monocytes arriving in the normal colon
do not upregulate calprotectin until they are partway
through the process of differentiation into macrophages
(Prof Allan Mowat, personal communication). As
calprotectin can amplify macrophage- and neutrophil-
mediated inflammatory responses [50, 51], the recruit-
ment of calprotectin-expressing macrophages may have
a detrimental effect on the brain.
The infiltration of the brain by myeloid cells was ac-
companied by sustained accumulation of CD8+ T cells,
NK cells and NKT cells. Infiltrating T cells were almost
exclusively CD62L−CD44hi, consistent with the dogma
that only activated T cells can enter the brain paren-
chyma [52]. The high proportion of lymphocytes, par-
ticularly CD8+ T cells, present in the brain following
systemic LPS challenge was a novel and surprising find-
ing. Each of these populations is known to be strong
producers of IFNγ [53, 54], which can have a highly det-
rimental impact on brain function [55–57]. IFNγ is also
a potent inducer of indoleamine-2,3-dioxygenase, which
can mediate behavioural changes through the metabol-
ism of tryptophan [58]. As before, the question arises of
what these lymphocyte populations might be doing in a
tissue where prevention of pathology would seem of
paramount importance. We have shown previously that
this protocol of LPS administration triggered a type-1
IFN response in the brain [13]. As both type I and type
II IFNs are a classic hallmark of anti-viral immunity,
these findings could again support the idea that the T
cell response in the brain reflects enhanced lymphocyte-
mediated immunosurveillance in anticipation of a poten-
tial viral threat.
High doses of LPS are an aggressive assault on the per-
ipheral immune system and have been used to model
sepsis [59], as well as sickness behaviour and immune-
mediated depression-like behaviour in rodents [6–8].
However, it should be noted that leukocyte recruitment
to the brain also occurs in response to inflammatory
stimuli other than LPS and does not require such an ag-
gressive stimulus. Indeed, we have previously reported
increased expression of chemokines and infiltration of
monocytes, T cells and NK cells in the brain following
TLR7/8 induced skin inflammation [15]. Interestingly,
these effects were not recapitulated by I.P. administra-
tion of TLR7/8 ligand, suggesting that the response of
the brain to systemic inflammation may depend on both
the nature and location of the stimulus. Furthermore,
De Mello and colleagues demonstrated a CCR2-
mediated recruitment of monocytes to the brain follow-
ing hepatic inflammation [16]. Collectively, these find-
ings add weight to the notion that leukocyte trafficking
to the brain may play a key role in immune-to-brain
communication that has previously been overlooked. Fur-
ther experiments will be required to establish the precise
contextual requirements necessary for leukocyte recruit-
ment to the brain in response to systemic inflammation.
Neuropsychiatric symptoms, such as depression and
anxiety, are common comorbidities in patients suffering
from chronic inflammatory disorders, such as rheuma-
toid and psoriatic arthritis, multiple sclerosis and inflam-
matory bowel diseases [1–5]. These comorbidities
represent a major burden both to patients and the health
care system since they are associated with a poorer clin-
ical outcome. The exact mechanisms underlying these
effects remain to be determined with certainty. However,
although it is difficult to examine biological pathways
(such as leukocyte infiltration of the brain) in clinical
practice, recent work shows that leukocyte recruitment
to the brain vasculature and/or parenchyma may con-
tribute to clinically relevant behavioural phenotypes in
mice. For example, the production of IL-1β by mono-
cytes adherent to the cerebral vasculature is responsible
for driving anxiety behaviour in response to social stress
in mice [60]. Similar processes may be involved in the
long-lasting cognitive impairments that have been re-
ported in humans 12–18months after sepsis-associated
delirium [41]. In support of this, mice infected with Sal-
monella pneumonia have increased rolling and adhesion
of monocytes and neutrophils to the BBB and the associ-
ated cognitive impairments can be prevented by blocking
monocyte recruitment to the vasculature [41]. Therefore,
recruitment of leukocytes to the cerebral vasculature
and/or the brain parenchyma may contribute to behav-
ioural changes following sustained endotoxin exposure
or in chronic inflammatory disease (Fig. 5).
Cytokines such as type-1 IFNs, IFNγ, TNFα and IL-1β
can affect brain homeostasis and consequently have also
been implicated in driving neuropsychiatric symptoms
associated with chronic inflammation, as has altered me-
tabolism of tryptophan via IDO [6–10]. Systemic LPS
challenge is one of the most widely used models for
studying the effects of peripheral immune activation on
behaviour [6–8]. As well as triggering acute, cytokine-
induced sickness behaviours, such as fever, anorexia and
decreased motor function, it also induces more pro-
longed depression-like behaviours such as anhedonia
and social withdrawal [6]. Repeated LPS challenge also
triggers behavioural changes [61] that are likely to reflect
a combination of cytokine-mediated effects and recruit-
ment of leukocytes to the brain. We have previously re-
ported that TLR7/8-mediated skin inflammation leads to
leukocyte recruitment to the brain and this is associated
with behavioural changes and reduced hippocampal
neurogenesis [15]. Further studies using specific chemo-
kine receptor-deficient mice or integrin-specific anti-
bodies to block leukocyte recruitment will be required
to determine directly whether this process causes
changes in behaviour in the current model of repeated
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LPS challenge. Characterising the leukocyte infiltrate in
the brain following different models of peripheral in-
flammation and understanding how this contributes to
the local inflammatory or metabolic milieu could be a
crucial step towards the generation of novel therapeutic
strategies to ameliorate depressive symptoms in patients
suffering from chronic inflammatory disorders.
Conclusions
In summary, prolonged exposure to LPS in the periphery
triggers a robust induction of chemokine transcription
in the brain, accompanied by the recruitment of myeloid
cells and lymphocytes to the brain parenchyma. The
downstream implications of such a response remain un-
clear. However, by altering brain homeostasis, cytokines,
chemokines and metabolites produced by infiltrating im-
mune cells have the potential to profoundly impact brain
function, mood and behaviour. This study adds weight
to the notion that leukocyte recruitment to the brain
may serve as a novel route of neuroimmune communi-
cation and opens the door to exploring similar phenom-
ena using different peripheral inflammatory stimuli.
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Additional files 1: Figure S1. Daily LPS injections triggered a robust
egress of myeloid cells from the bone marrow but a subdued peripheral
cytokine response. (A) Experimental model. Mice were injected with LPS
or vehicle at days 0, 1, 2, 3, 4, 5 and 6, and sacrificed at 6 hours following
initial injection, and at days 2, 5 and 7, 24 hours after their final injection.
(B) Change in body weight was monitored throughout the model. (C)
Flow cytometry gating strategy of circulating CD11b+Ly6G+Ly6Cint
neutrophils and CD11b+Ly6G-Ly6C+ monocytes. (D) Percentage of
circulating CD11b+Ly6G+Ly6Cint neutrophils and CD11b+Ly6G-Ly6C+
monocytes as a proportion of single, live, CD45+ cells in the blood. Data
show means ± 1SD. n=5/group. Data representative of two independent
experiments. (E) Plasma concentrations of IL-1β, TNFα and IL-6 at 6 hours
and day 2, 5 and 7 of the LPS model. n=5-8/group. Significance was cal-
culated using two-way ANOVA: *p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001.
Additional files 2: Figure S2. Temporal expression of chemokines and
their receptors in brain and by PBL following daily LPS injections. Gene
expression analysis of (A) chemokines and (B) chemokine receptors in the
brain and by PBL following daily systemic LPS injections for 2, 5 and 7 days
as determined by QPCR. Gene expression was normalised to that of Tbp.
Fold change was calculated by comparing the normalised gene expression
values of each sample to the mean expression level of the control group
using the ΔΔCT method. Significance was calculated using two-way ANOVA:
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. n=4/group.
Additional files 3: Figure S3. Proportions of CD45hi leukocytes in the
brains of LPS and vehicle-treated mice. (A) Gating strategy and represen-
tative plots of single, live, CD45+ cells from mice injected with LPS or ve-
hicle for 2, 5 or 7 consecutive days. (B) Relative and proportion of CD45int
and CD45hi cells and (C) percentage of CD45hi cells in the brain. The lat-
ter shown as a percentage of all single, live CD45+ cells. n=3 (vehicle) n=
5 (LPS). (D) Cd45 transcript abundance determined by QPCR and normal-
ised to that of Tbp. Fold change was calculated by comparing the nor-
malised gene expression values of each sample to the mean expression
level of the control group using the ΔΔCT method. n=4/group. Signifi-
cance was calculated using two-way ANOVA: **p≤0.01, ***p≤0.001.
Additional files 4: Figure S4. Flow cytometry gating strategy for
infiltrating leukocytes. (A) Myeloid cell gating strategy. CD11b+ cells were
identified from single, live CD45hi leukocytes in the brain. Macrophages
(MØ) were further identified as being F4/80+Ly6C- and (i) were divided
into two populations based on MHC class II expression. Neutrophils were
F4/80-Ly6Cint and (ii) Ly6G+. Monocytes were F4/80+Ly6Chi and (iii) Ly6G-.
(B) Lymphocyte gating strategy. Single, live CD45hi leukocytes were split
into NK1.1+TCRβ- NK cells, NK1.1+TCRβ+ NKT cells and NK1.1-TCRβ+ T
lymphocytes. NK1.1-TCRβ+ T lymphocytes were then further separated
based on the expression of CD4 and CD8. (C) Representative plots
showing expression of CD62L and CD44 by CD4+ and CD8+ T cells in the
brain.
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